Spruce Biosciences SPRB Stock
Spruce Biosciences Price Chart
Spruce Biosciences SPRB Financial and Trading Overview
| Spruce Biosciences stock price | 0.7 USD |
| Previous Close | 2.37 USD |
| Open | 2.37 USD |
| Bid | 0 USD x 2200 |
| Ask | 0 USD x 1800 |
| Day's Range | 2.36 - 2.48 USD |
| 52 Week Range | 0.96 - 3.57 USD |
| Volume | 132.84K USD |
| Avg. Volume | 162.37K USD |
| Market Cap | 93.8M USD |
| Beta (5Y Monthly) | 2.288198 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.5 USD |
SPRB Valuation Measures
| Enterprise Value | -18425706 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4658384 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 47.76008 |
| Price/Book (mrq) | 0.868605 |
| Enterprise Value/Revenue | -9.382 |
| Enterprise Value/EBITDA | 0.379 |
Trading Information
Spruce Biosciences Stock Price History
| Beta (5Y Monthly) | 2.288198 |
| 52-Week Change | 55.26% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.57 USD |
| 52 Week Low | 0.96 USD |
| 50-Day Moving Average | 2.23 USD |
| 200-Day Moving Average | 1.89 USD |
SPRB Share Statistics
| Avg. Volume (3 month) | 162.37K USD |
| Avg. Daily Volume (10-Days) | 233.06K USD |
| Shares Outstanding | 39.75M |
| Float | 11.15M |
| Short Ratio | 2.83 |
| % Held by Insiders | 0.20% |
| % Held by Institutions | 71.87% |
| Shares Short | 470.88K |
| Short % of Float | 1.50% |
| Short % of Shares Outstanding | 1.17% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2482.12% |
| Gross Margin | -63.13% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.98% |
| Return on Equity (ttm) | -45.34% |
Income Statement
| Revenue (ttm) | 1.96M USD |
| Revenue Per Share (ttm) | 0.08 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -48677000 USD |
| Net Income Avi to Common (ttm) | -47209000 USD |
| Diluted EPS (ttm) | -1.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 118.59M USD |
| Total Cash Per Share (mrq) | 2.98 USD |
| Total Debt (mrq) | 5.96M USD |
| Total Debt/Equity (mrq) | 5.52 USD |
| Current Ratio (mrq) | 5.968 |
| Book Value Per Share (mrq) | 2.717 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -41647000 USD |
| Levered Free Cash Flow (ttm) | -29097124 USD |
Profile of Spruce Biosciences
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 611 Gateway Boulevard |
| ZIP | 94080 |
| Phone | (415) 655-4168 |
| Website | https://www.sprucebiosciences.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 30 |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Q&A For Spruce Biosciences Stock
What is a current SPRB stock price?
Spruce Biosciences SPRB stock price today per share is 0.7 USD.
How to purchase Spruce Biosciences stock?
You can buy SPRB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Spruce Biosciences?
The stock symbol or ticker of Spruce Biosciences is SPRB.
Which industry does the Spruce Biosciences company belong to?
The Spruce Biosciences industry is Biotechnology.
How many shares does Spruce Biosciences have in circulation?
The max supply of Spruce Biosciences shares is 43.44M.
What is Spruce Biosciences Price to Earnings Ratio (PE Ratio)?
Spruce Biosciences PE Ratio is now.
What was Spruce Biosciences earnings per share over the trailing 12 months (TTM)?
Spruce Biosciences EPS is -1.24 USD over the trailing 12 months.
Which sector does the Spruce Biosciences company belong to?
The Spruce Biosciences sector is Healthcare.
Spruce Biosciences SPRB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}